The research organization in Beerse has been incorporated into a single global organization, together with research centers in other European countries and in the USA, dedicated to five core research areas: neurosciences, infectious diseases and vaccines, oncology, immunology and cardiovascular & metabolic conditions. The focus in Beerse is above all on research in the first four areas. Tibotec and Virco (link to T-V’s Internet site), sister companies, primarily dedicated to research into infectious diseases (HIV/aids, tuberculosis, hepatitis C), also moved to the Beerse campus in 2010.
The two pharmaceutical factories in Beerse mainly concentrate on the production of liquid and semi-solid drug forms. Like the chemical production factories in Geel, they are part of the worldwide supply chain organization that plays a central role in worldwide supply logistics. Our aim is to always make reliable drugs quickly and efficiently available to the patients who need them, wherever they are in the world. There is also the Preservation & Material Protection department (link to the PMP Internet site). Last but not least, there are also a number of support services based in Beerse, which are mainly active locally, but also internationally. They strengthen the importance of the campus as a crucial link in the worldwide network of companies.
At the Beerse II company site houses the financial coordination centers, the worldwide computer support and Janssen Animal Health. From half of September 2010 the Janssen-Cilag Benelux marketing and sales organization will also operate from Beerse II.
A specialized factory concentrating on the production of medicinal drugs in the form of pellets, has been in operation in Olen since 1992.
In just a few decades, Janssen in Geel has developed into one of the most innovative and successful chemical production centers in the world. Within the network strategy of the worldwide supply chain, the Geel site is the only site to be recognized as a launch and development site for the production of active chemical ingredients that are then processed further in the pharmaceutical production factories in Beerse and abroad. The site has cutting-edge technology installations at its disposal, including hydrogenation and bromination installations. A new trials factory that will play a key role within the global production network will be operational soon.
The Jan Palfijn hospital in Merksem houses a clinical research unit specifically dedicated to Phase I clinical research (with healthy volunteers).